Indications for TEFLARO:
Susceptible acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
≥18yrs: Give by IV infusion over 5–60mins. CrCl >50mL/min: 600mg every 12hrs. Renal impairment (CrCl >30–≤50mL/min): 400mg every 12hrs; (CrCl ≥15–≤30mL/min): 300mg every 12hrs; ESRD (including hemodialysis): 200mg every 12hrs (dose after dialysis on dialysis days). ABSSSI: treat for 5–14 days. CABP: treat for 5–7 days.
Give by IV infusion over 30–60mins (<2mos) or 5–60mins (≥2mos). ABSSSI: <34wks gestational age and <12 days postnatal age: not established. Newborn (≥34wks gestational age and ≥12 days postnatal age) to <2mos: 6mg/kg every 8hrs. 2mos–<2yrs: 8mg/kg every 8hrs. ≥2yrs–<18yrs (≤33kg): 12mg/kg every 8hrs; (>33kg): 400mg every 8hrs or 600mg every 12hrs. CABP: <2mos: not established. 2mos–<2yrs: 8mg/kg every 8hrs. ≥2yrs–<18yrs (≤33kg): 12mg/kg every 8hrs; (>33kg): 400mg every 8hrs or 600mg every 12hrs. All: treat for 5–14 days.
Penicillin or other beta-lactam allergy. Monitor for hemolytic anemia. Pregnancy. Nursing mothers.
May cause false (+) direct Coomb's test.
Diarrhea, nausea, vomiting, pyrexia, rash; C. difficile-associated diarrhea, hypersensitivity reactions (discontinue if occur), neurological reactions.
Generic Drug Availability:
Single-dose vials—1, 10